Roivant Sciences Ltd

NASDAQ:ROIV   2:33:15 PM EDT
3.16
-0.17 (-5.11%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.22B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$7.08 Million
Adjusted EPS-$0.39
See more estimates
10-Day MA$3.21
50-Day MA$3.72
200-Day MA$5.21
See more pivots

Roivant Sciences Ltd Stock, NASDAQ:ROIV

11-12 St. James's Square, Suite 1, 3rd Floor, London, Greater London SW1Y 4LB
Bermuda
Phone: +44.207.400.3347
Number of Employees: 863

Description

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.